Presented by the Cancer Drug Development Forum (CDDF) in collaboration with the Society for Immunotherapy of Cancer
SITC is collaborating with the Cancer Drug Development Forum (CDDF) on the third European meeting that provides a platform for preclinical and clinical researchers in the field of immunotherapy. The concept is timely and necessary as agents have been licensed and arrived in clinical practice and many more similar drugs are expected to follow.
The goal of the conference is to provide a forum for discussion of early clinical drug development and address the unique challenges of drug development. ITOC is designed to provide a highly interactive platform. In so doing, it attracts a multi-stakeholder attendance connecting preclinical and clinical scientists, clinicians, healthcare professionals, academia and other stakeholders who are involved in the development of novel anticancer agents. ITOC is renowned within its audience for the highly scientific character of its lectures.
SITC Board of Directors President, Dr. Howard L. Kaufman, is serving as Co-President of the conference, together with Dr. Alexander M.M. Eggermont and Dr. Volkmar Nüssler. SITC Board of Directors Vice President Dr. Lisa Butterfield is on the Scientific Committee for the program.
Get more information here.